NURS 676 ADVANCED PHARMACOLOGY MIDTERM EXAM COMPLETE PRACTICE
TEST BANK QUESTIONS AND ANSWERS | VERIFIED SOLUTIONS | COMPREHENSIVE
STUDY GUIDE | UPDATED 2026/2027 (WEST COAST UNIVERSITY – WCU)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━
NURS 676 ADVANCED PHARMACOLOGY MIDTERM EXAM
2026/2027 EDITION
━━━━━━━━━━━━━━━━━━━━━━━━━━━━
COMPLETE PRACTICE EXAM
100+ MULTIPLE-CHOICE QUESTIONS
PASSING SCORE: 70%
TESTING TIME: 120 MINUTES
━━━━━━━━━━━━━━━━━━━━━━━━━━━━
TABLE OF CONTENTS
Advanced Pharmacokinetics
Pharmacodynamics & Receptor Theory
Autonomic Nervous System Pharmacology
Cardiovascular Pharmacotherapeutics
Endocrine Pharmacology
Antimicrobial Therapy
Pain Management & Controlled Substances
Special Populations & Prescribing Considerations
Adverse Drug Reactions & Drug Interactions
Evidence-Based Prescribing & Clinical Decision-Making
WEST COAST UNIVERSITY (WCU) || ALIGNED WITH CURRENT ADVANCED PRACTICE
NURSING PHARMACOLOGY BLUEPRINTS || ADVANCED PRESCRIBING PRINCIPLES ||
PROFESSIONAL STUDY GUIDE || 100% VERIFIED | GRADED A+ || COMPREHENSIVE
EXAM PREPARATION || PREPARED FOR ADVANCED PRACTICE NURSING EDUCATION ||
PROFESSIONAL EXAMINATION USE
ADVANCED PHARMACOKINETICS & PHARMACODYNAMICS
Q1. A 72-year-old patient with chronic kidney disease stage 4 is prescribed a
medication primarily eliminated through renal excretion. Which pharmacokinetic
,alteration is most likely to occur?
A. Reduced bioavailability
B. Increased hepatic metabolism
C. Increased drug half-life
D. Increased first-pass metabolism
Correct Answer: 🔴 C. Increased drug half-life
Explanation: 🔹 Reduced renal clearance results in prolonged drug elimination and
an increased half-life. This can lead to drug accumulation and toxicity unless dosage
adjustments are made. Reduced bioavailability and first-pass metabolism are
unrelated to renal impairment, while hepatic metabolism may remain unchanged
depending on the drug.
Q2. A nurse practitioner prescribes a highly protein-bound medication to a patient
with severe hypoalbuminemia. What is the primary clinical concern?
A. Reduced free-drug concentration
B. Increased therapeutic resistance
C. Increased free-drug concentration and toxicity
D. Accelerated renal elimination
Correct Answer: 🔴 C. Increased free-drug concentration and toxicity
Explanation: 🔹 Albumin binds many medications. Low albumin levels result in more
unbound drug available for pharmacologic activity, increasing toxicity risk. Renal
elimination may not increase proportionally, and therapeutic resistance is not
expected.
Q3. Which statement best describes a competitive antagonist?
A. Permanently binds receptors
B. Binds receptors and activates them weakly
C. Competes with agonists for receptor binding sites
D. Prevents receptor synthesis
,Correct Answer: 🔴 C. Competes with agonists for receptor binding sites
Explanation: 🔹 Competitive antagonists reversibly occupy receptor sites, preventing
agonist binding. Their effects can often be overcome by increasing agonist
concentration. They do not activate receptors or permanently alter receptor
production.
Q4. A medication exhibits zero-order kinetics. Which characteristic is expected?
A. Constant percentage eliminated per unit time
B. Constant amount eliminated per unit time
C. Elimination independent of concentration gradients
D. Complete renal elimination
Correct Answer: 🔴 B. Constant amount eliminated per unit time
Explanation: 🔹 Zero-order kinetics occur when elimination pathways become
saturated. A fixed amount, rather than a percentage, is eliminated over time.
Examples include ethanol and high-dose phenytoin.
Q5. A patient receives repeated doses of a drug. Steady-state concentration is
generally achieved after:
A. One half-life
B. Two half-lives
C. Four to five half-lives
D. Ten half-lives
Correct Answer: 🔴 C. Four to five half-lives
Explanation: 🔹 Most drugs reach steady state after approximately four to five half-
lives. At this point, drug administration equals elimination, resulting in stable
plasma concentrations.
Q6. Which factor most significantly increases drug bioavailability?
, A. Extensive first-pass metabolism
B. Intravenous administration
C. Delayed gastric emptying
D. Increased protein binding
Correct Answer: 🔴 B. Intravenous administration
Explanation: 🔹 Intravenous administration provides 100% bioavailability because
the drug enters systemic circulation directly. Oral medications may undergo
incomplete absorption and first-pass metabolism.
AUTONOMIC NERVOUS SYSTEM PHARMACOLOGY
Q7. A patient taking propranolol develops bradycardia. Which receptor blockade is
primarily responsible?
A. Alpha-1 receptor
B. Beta-1 receptor
C. Beta-2 receptor
D. Muscarinic receptor
Correct Answer: 🔴 B. Beta-1 receptor
Explanation: 🔹 Beta-1 receptors are located primarily in the heart. Blockade
decreases heart rate, contractility, and conduction velocity, leading to bradycardia.
Q8. Which adverse effect is commonly associated with nonselective beta-blockers?
A. Bronchodilation
B. Hyperthyroidism
C. Bronchoconstriction
D. Mydriasis
Correct Answer: 🔴 C. Bronchoconstriction
Explanation: 🔹 Nonselective beta-blockers inhibit beta-2 receptors in the lungs,
potentially causing bronchoconstriction and worsening asthma or COPD symptoms.
TEST BANK QUESTIONS AND ANSWERS | VERIFIED SOLUTIONS | COMPREHENSIVE
STUDY GUIDE | UPDATED 2026/2027 (WEST COAST UNIVERSITY – WCU)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━
NURS 676 ADVANCED PHARMACOLOGY MIDTERM EXAM
2026/2027 EDITION
━━━━━━━━━━━━━━━━━━━━━━━━━━━━
COMPLETE PRACTICE EXAM
100+ MULTIPLE-CHOICE QUESTIONS
PASSING SCORE: 70%
TESTING TIME: 120 MINUTES
━━━━━━━━━━━━━━━━━━━━━━━━━━━━
TABLE OF CONTENTS
Advanced Pharmacokinetics
Pharmacodynamics & Receptor Theory
Autonomic Nervous System Pharmacology
Cardiovascular Pharmacotherapeutics
Endocrine Pharmacology
Antimicrobial Therapy
Pain Management & Controlled Substances
Special Populations & Prescribing Considerations
Adverse Drug Reactions & Drug Interactions
Evidence-Based Prescribing & Clinical Decision-Making
WEST COAST UNIVERSITY (WCU) || ALIGNED WITH CURRENT ADVANCED PRACTICE
NURSING PHARMACOLOGY BLUEPRINTS || ADVANCED PRESCRIBING PRINCIPLES ||
PROFESSIONAL STUDY GUIDE || 100% VERIFIED | GRADED A+ || COMPREHENSIVE
EXAM PREPARATION || PREPARED FOR ADVANCED PRACTICE NURSING EDUCATION ||
PROFESSIONAL EXAMINATION USE
ADVANCED PHARMACOKINETICS & PHARMACODYNAMICS
Q1. A 72-year-old patient with chronic kidney disease stage 4 is prescribed a
medication primarily eliminated through renal excretion. Which pharmacokinetic
,alteration is most likely to occur?
A. Reduced bioavailability
B. Increased hepatic metabolism
C. Increased drug half-life
D. Increased first-pass metabolism
Correct Answer: 🔴 C. Increased drug half-life
Explanation: 🔹 Reduced renal clearance results in prolonged drug elimination and
an increased half-life. This can lead to drug accumulation and toxicity unless dosage
adjustments are made. Reduced bioavailability and first-pass metabolism are
unrelated to renal impairment, while hepatic metabolism may remain unchanged
depending on the drug.
Q2. A nurse practitioner prescribes a highly protein-bound medication to a patient
with severe hypoalbuminemia. What is the primary clinical concern?
A. Reduced free-drug concentration
B. Increased therapeutic resistance
C. Increased free-drug concentration and toxicity
D. Accelerated renal elimination
Correct Answer: 🔴 C. Increased free-drug concentration and toxicity
Explanation: 🔹 Albumin binds many medications. Low albumin levels result in more
unbound drug available for pharmacologic activity, increasing toxicity risk. Renal
elimination may not increase proportionally, and therapeutic resistance is not
expected.
Q3. Which statement best describes a competitive antagonist?
A. Permanently binds receptors
B. Binds receptors and activates them weakly
C. Competes with agonists for receptor binding sites
D. Prevents receptor synthesis
,Correct Answer: 🔴 C. Competes with agonists for receptor binding sites
Explanation: 🔹 Competitive antagonists reversibly occupy receptor sites, preventing
agonist binding. Their effects can often be overcome by increasing agonist
concentration. They do not activate receptors or permanently alter receptor
production.
Q4. A medication exhibits zero-order kinetics. Which characteristic is expected?
A. Constant percentage eliminated per unit time
B. Constant amount eliminated per unit time
C. Elimination independent of concentration gradients
D. Complete renal elimination
Correct Answer: 🔴 B. Constant amount eliminated per unit time
Explanation: 🔹 Zero-order kinetics occur when elimination pathways become
saturated. A fixed amount, rather than a percentage, is eliminated over time.
Examples include ethanol and high-dose phenytoin.
Q5. A patient receives repeated doses of a drug. Steady-state concentration is
generally achieved after:
A. One half-life
B. Two half-lives
C. Four to five half-lives
D. Ten half-lives
Correct Answer: 🔴 C. Four to five half-lives
Explanation: 🔹 Most drugs reach steady state after approximately four to five half-
lives. At this point, drug administration equals elimination, resulting in stable
plasma concentrations.
Q6. Which factor most significantly increases drug bioavailability?
, A. Extensive first-pass metabolism
B. Intravenous administration
C. Delayed gastric emptying
D. Increased protein binding
Correct Answer: 🔴 B. Intravenous administration
Explanation: 🔹 Intravenous administration provides 100% bioavailability because
the drug enters systemic circulation directly. Oral medications may undergo
incomplete absorption and first-pass metabolism.
AUTONOMIC NERVOUS SYSTEM PHARMACOLOGY
Q7. A patient taking propranolol develops bradycardia. Which receptor blockade is
primarily responsible?
A. Alpha-1 receptor
B. Beta-1 receptor
C. Beta-2 receptor
D. Muscarinic receptor
Correct Answer: 🔴 B. Beta-1 receptor
Explanation: 🔹 Beta-1 receptors are located primarily in the heart. Blockade
decreases heart rate, contractility, and conduction velocity, leading to bradycardia.
Q8. Which adverse effect is commonly associated with nonselective beta-blockers?
A. Bronchodilation
B. Hyperthyroidism
C. Bronchoconstriction
D. Mydriasis
Correct Answer: 🔴 C. Bronchoconstriction
Explanation: 🔹 Nonselective beta-blockers inhibit beta-2 receptors in the lungs,
potentially causing bronchoconstriction and worsening asthma or COPD symptoms.
